Related Experiment Videos
Regression of left ventricular hypertrophy
H Eichstaedt1, R J Schroeder, W Auffermann
1Department of Cardiology, University Hospital Rudolf Virchow, Free University, Berlin, Germany.
Insights
Carvedilol effectively reduces left ventricular hypertrophy in hypertensive patients. This study shows significant septal thickness reduction and improved diastolic blood pressure after 6 months of treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Left ventricular hypertrophy (LVH) is a significant concern in hypertension management.
- Hypertrophy regression is an increasingly important therapeutic target.
- Magnetic Resonance Imaging (MRI) is utilized to assess cardiac structural changes.
Purpose of the Study:
- To evaluate the efficacy of carvedilol in reducing left ventricular hypertrophy in patients with hypertension.
- To assess the impact of carvedilol on diastolic blood pressure and cardiac function.
Main Methods:
- Seventeen patients with diastolic blood pressure ≥ 95 mm Hg and left ventricular wall thickness ≥ 15 mm were enrolled.
- Patients received 25 mg/day carvedilol for 6 months.
- Measurements included MRI for septal thickness and radionuclide ventriculography for ejection fraction and wall motion, before and after treatment.
Main Results:
- Carvedilol significantly reduced septal thickness from 17.7 mm to 16.3 mm (p < 0.05).
- Diastolic blood pressure decreased significantly from 98.0 mm Hg to 88.7 mm Hg (p < 0.05).
- No significant changes were observed in left ventricular ejection fraction or wall motion.
Conclusions:
- Carvedilol is effective in inducing regression of left ventricular hypertrophy in hypertensive patients.
- The drug also significantly lowers diastolic blood pressure.
- Treatment with carvedilol did not adversely affect left ventricular systolic function or regional wall motion.
Abstract:
Since our first studies on hypertrophy regression, this parameter has achieved an increasing interest in the treatment of hypertension. During the past 8 years we studied different groups of antihypertensive drugs with the use of magnetic resonance imaging (MRI). This article discusses the antihypertensive drug carvedilol. We examined 17 patients with diastolic blood pressure of at least 95 mm Hg and left ventricular wall thickness of at least 15 mm. Measurements were carried out before and after treatment with 25 mg/day carvedilol for 6 months. We demonstrated a significant regression of septal thickness from 17.7 to 16.3 mm. At each wall, three measurements at different points were performed by MRI and the means were calculated. Left ventricular ejection fraction and wall motion did not show any significant changes in radionuclide ventriculography after treatment. The diastolic blood pressure was reduced from 98.0 to 88.7 mm Hg. All differences are significant (p less than 0.05). There was no significant correlation between the extent of regression of septal hypertrophy and the degree of pretherapeutic hypertrophy, the age of patients, or the dimension of blood pressure reduction.